Publication
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (9)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 9
- cancerMalignant Colorectal Neoplasmcivic_curation1.00
- drugPanitumumabcivic_curation1.00
- geneKRAScivic_curation1.00
- variantKRAS G12Ccivic_curation1.00
- variantKRAS G12Dcivic_curation1.00
- variantKRAS G12/G13civic_curation1.00
- variantKRAS G12Rcivic_curation1.00
- variantKRAS G12Scivic_curation1.00
- variantKRAS G12Vcivic_curation1.00
Curated evidence
Evidence citing this paper (7)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 18316791
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| KRAS G12C1 | ||||||||
| Panitumumab | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | C | Supports Resistance | 3 | accepted | EID2253In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced… (full text at CIViC) PMID 18316791 · Amado et al., 2008 · Open in CIViC | civic |
| KRAS G12D1 | ||||||||
| Panitumumab | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | C | Supports Resistance | — | accepted | EID2236In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced… (full text at CIViC) PMID 18316791 · Amado et al., 2008 · Open in CIViC | civic |
| KRAS G12/G132 | ||||||||
| (prognostic) | Malignant Colorectal NeoplasmCURATED_BROADER | Prognostic | B | Does Not Support Poor Outcome | 3 | accepted | EID2231In a retrospective study of 427 chemotherapy-refractory metastatic colorectal patients treated with either panitumumab monotherapy or best supportive care (BSC), KRAS codon 12 or 13 mutations were obs… (full text at CIViC) PMID 18316791 · Amado et al., 2008 · Open in CIViC | civic |
| Panitumumab | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | B | Supports Resistance | 3 | accepted | EID2004In a retrospective study of 427 chemotherapy-refractory metastatic colorectal patients treated with either panitumumab monotherapy or best supportive care (BSC), KRAS codon 12 or 13 mutations were obs… (full text at CIViC) PMID 18316791 · Amado et al., 2008 · Open in CIViC | civic |
| KRAS G12R1 | ||||||||
| Panitumumab | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | C | Supports Resistance | — | accepted | EID2264In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced… (full text at CIViC) PMID 18316791 · Amado et al., 2008 · Open in CIViC | civic |
| KRAS G12S1 | ||||||||
| Panitumumab | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | C | Supports Resistance | — | accepted | EID2269In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced… (full text at CIViC) PMID 18316791 · Amado et al., 2008 · Open in CIViC | civic |
| KRAS G12V1 | ||||||||
| Panitumumab | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | C | Supports Resistance | — | accepted | EID2232In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced… (full text at CIViC) PMID 18316791 · Amado et al., 2008 · Open in CIViC | civic |